Cargando…

Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses

Cellular heterogeneity is a major cause of treatment resistance in cancer. Despite recent advances in single-cell genomic and transcriptomic sequencing, it remains difficult to relate measured molecular profiles to the cellular activities underlying cancer. Here, we present an integrated experimenta...

Descripción completa

Detalles Bibliográficos
Autores principales: Contreras-Trujillo, Humberto, Eerdeng, Jiya, Akre, Samir, Jiang, Du, Contreras, Jorge, Gala, Basia, Vergel-Rodriguez, Mary C., Lee, Yeachan, Jorapur, Aparna, Andreasian, Areen, Harton, Lisa, Bramlett, Charles S., Nogalska, Anna, Xiao, Gang, Lee, Jae-Woong, Chan, Lai N., Müschen, Markus, Merchant, Akil A., Lu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586369/
https://www.ncbi.nlm.nih.gov/pubmed/34764253
http://dx.doi.org/10.1038/s41467-021-26771-1
Descripción
Sumario:Cellular heterogeneity is a major cause of treatment resistance in cancer. Despite recent advances in single-cell genomic and transcriptomic sequencing, it remains difficult to relate measured molecular profiles to the cellular activities underlying cancer. Here, we present an integrated experimental system that connects single cell gene expression to heterogeneous cancer cell growth, metastasis, and treatment response. Our system integrates single cell transcriptome profiling with DNA barcode based clonal tracking in patient-derived xenograft models. We show that leukemia cells exhibiting unique gene expression respond to different chemotherapies in distinct but consistent manners across multiple mice. In addition, we uncover a form of leukemia expansion that is spatially confined to the bone marrow of single anatomical sites and driven by cells with distinct gene expression. Our integrated experimental system can interrogate the molecular and cellular basis of the intratumoral heterogeneity underlying disease progression and treatment resistance.